Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.
Efficacy data for PARP inhibitors for the treatment of metastatic triple-negative breast cancer77
| Treatment Regimena | ORR (%) | PFS (months) | OS (months) |
|---|---|---|---|
| Chemo alone | 16 | 3.3 | 5.7 |
| Chemo + BSI 201 | 48 | 6.9 | 9.2 |
Patients were randomized to receive either Carboplatin + Gemcitabine (chemo) alone or Carboplatin + Gemcitabine + BSI 201 (PARP-I; iniparib).
Chemo = chemotherapy; ORR = overall response rate; OS = overall survival; PARP = poly ADP-ribose polymerase; PFS = progression-free survival
